Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Zacks Investment Research on MSN1d
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
Sarepta Therapeutics SRPT shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?
Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...
Sarepta price target lowered to $80 from $105 at Scotiabank
Scotiabank lowered the firm’s price target on Sarepta (SRPT) to $80 from $105 and keeps a Sector Perform rating on the shares. After speaking ...
Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at ...
BioSpace16h
In Wake of Elevydis Death, Duchenne Patient Community Vows to Push On
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevydis, patient advocacy group Parent ...
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...